Publication | Open Access
Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods
143
Citations
25
References
2016
Year
Drug TargetMolecular BiologyTumor BiologyMyeloid NeoplasiaHematological MalignancyMedicinal ChemistryAnti-cancer AgentMyeloid Cell Leukemia-1Radiation OncologyMedicineDrug DevelopmentPharmacologyHydrophobic PocketsNatural SciencesRational Drug DesignBinding GrooveMolecular DockingDrug DiscoveryFragment-based Methods
Myeloid cell leukemia-1 (Mcl-1) is a member of the Bcl-2 family of proteins responsible for the regulation of programmed cell death. Amplification of Mcl-1 is a common genetic aberration in human cancer whose overexpression contributes to the evasion of apoptosis and is one of the major resistance mechanisms for many chemotherapies. Mcl-1 mediates its effects primarily through interactions with pro-apoptotic BH3 containing proteins that achieve high affinity for the target by utilizing four hydrophobic pockets in its binding groove. Here we describe the discovery of Mcl-1 inhibitors using fragment-based methods and structure-based design. These novel inhibitors exhibit low nanomolar binding affinities to Mcl-1 and >500-fold selectivity over Bcl-xL. X-ray structures of lead Mcl-1 inhibitors when complexed to Mcl-1 provided detailed information on how these small-molecules bind to the target and were used extensively to guide compound optimization.
| Year | Citations | |
|---|---|---|
Page 1
Page 1